Industry gets open say on European Commission technical role in cells/tissues
This article was originally published in Clinica
The European Commission is inviting by October 1 comments from the industry on its role in establishing and updating technical requirements in relation to the quality and safety of human tissues and cells, with specific reference to the donation, procurement and testing of these materials.
You may also be interested in...
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.
The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.